selekoa

A documentary history of machine intelligence.

Records found and checked by machines, not reviewed by an editor · What this means →

Record explorer

Explore the documentary record

Every claim links to its source passage,
its dates where known and its limits.

Institutional dossier

Roche

Built from the same claims and evidence as the map.

Institutional dossier

The documented history of Roche: chronology, people, research, capital and compute, and governance. Every statement opens its source and its limits.

Records dated 2021-12-07 to 2021-12-07 · 0 undated

1 claims · 1 sources · 1 not editorially accepted. The counts describe this selection. They do not measure completeness or independent confirmation.

Scope, evidence and limits

Description: F. Hoffmann-La Roche Ltd.

The records are grouped automatically. No human inspection of the selected claims, source paths or framing is recorded for this dossier. Each source passage shows how it was checked.

The dossier is computed from existing records. It is not a continuous history of the institution, and a missing record does not mean that an event or relationship did not happen. The chronology uses the dates of events and reports, not the date the public could first have known of them. Later sources can describe earlier events.

Select any statement to see its exact claim, qualification, date note, evidence passage, location in the source, source version and review status. The description above is Selekoa’s stored description of the institution, based on these sources:

Chronology

Records about the institution itself and documented changes to its frameworks, by year. Expand a year to read the claims. People’s other institutional records and related documents have their own sections. Where a date gives only the year or month, the order within it is unknown.

2021Record year · 1 claims
  1. 2021-12-07 · announcementinstitutions
    Recursion announced on 7 December 2021 a collaboration with Roche and Genentech in neuroscience and an oncology indication, under which it would receive an upfront payment of $150 million, and stated that Roche and Genentech may initiate up to 40 programs, each of which could yield more than $300 million in milestones if successfully developed and commercialized.Recursion Pharmaceuticals → announced a partnership with → RocheInspect claim & evidence ↗

    Record about this institution · Stated in source · Supported Announced

    Activity: announced

    Qualification and date notes

    Announced terms as Recursion states them. The milestone figures are conditional and per programme; they are not totalled, and the record does not establish payments received. Genentech is a party with Roche (the release names Genentech as a member of the Roche Group).

    Date of Recursion's press release.